Payment overview · 2025
General Payments
$596.31
31 reported records · 13 companies
Healthcare provider profile · identity verified
Sarah Lou Mccrary, APRN-CNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Gerontology · GREENVILLE, TX · NPI 1740896539
Verified facts
What the public records show
CMS Open Payments records show Sarah Lou Mccrary, APRN-CNP received $596.31 in general payments during 2025 across 31 reported records.
Axsome Therapeutics, Inc. accounted for 31.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $188.28 | 31.6% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $66.61 | 11.2% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $60.11 | 10.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $49.01 | 8.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $41.33 | 6.9% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $32.92 | 5.5% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $27.94 | 4.7% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $26.65 | 4.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.62 | 4.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.55 | 4.0% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.58 | 3.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.52 | 2.9% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $16.19 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $596.31 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $188.28 | 10 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $50.21 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $49.01 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $41.33 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $40.36 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $32.92 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $27.94 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $26.65 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $24.62 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $23.80 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.55 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $21.58 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.53 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.52 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.40 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $16.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 65 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
71 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
65 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 261 | 72 |
| Levothyroxine Sodium | Levothyroxine Sodium | 236 | 66 |
| Gabapentin | Gabapentin | 203 | 63 |
| Amlodipine Besylate | Amlodipine Besylate | 183 | 52 |
| Omeprazole | Omeprazole | 173 | 54 |
| Lisinopril | Lisinopril | 144 | 44 |
| Alprazolam | Alprazolam | 133 | 35 |
| Trazodone Hcl | Trazodone Hcl | 118 | 33 |
| Celecoxib | Celecoxib | 117 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 117 | 34 |
| Metformin Hcl | Metformin Hcl | 110 | 34 |
| Meloxicam | Meloxicam | 106 | 28 |
| Furosemide | Furosemide | 104 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 95 | 36 |
| Tramadol Hcl | Tramadol Hcl | 87 | 26 |
| Ezetimibe | Ezetimibe | 85 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 85 | 31 |
| Montelukast Sodium | Montelukast Sodium | 84 | 20 |
| Potassium Chloride | Potassium Chloride | 83 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 82 | 20 |
| Glimepiride | Glimepiride | 79 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 77 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 74 | 15 |
| Azithromycin | Azithromycin | 71 | 52 |
| Ozempic | Semaglutide | 71 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 26 |
| Allopurinol | Allopurinol | 67 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 21 |
| Losartan Potassium | Losartan Potassium | 66 | 24 |
| Eliquis | Apixaban | 65 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 63 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 63 | 22 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 61 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 28 |
| Prednisone | Prednisone | 55 | 46 |
| Pregabalin | Pregabalin | 54 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 54 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 44 |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 13 |
| Clonazepam | Clonazepam | 48 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 47 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 46 | 17 |
| Farxiga | Dapagliflozin Propanediol | 44 | suppressed |
| Fluconazole | Fluconazole | 44 | 16 |
| Carvedilol | Carvedilol | 43 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 35 |
| Mounjaro | Tirzepatide | 39 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 29 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 37 | 17 |
| Donepezil Hcl | Donepezil Hcl | 37 | 11 |
| Chlorthalidone | Chlorthalidone | 35 | suppressed |
| Torsemide | Torsemide | 33 | suppressed |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Methylprednisolone | Methylprednisolone | 30 | 29 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 23 |
| Lorazepam | Lorazepam | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | suppressed |
| Famotidine | Famotidine | 25 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | 13 |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 19 | 14 |
| Valsartan | Valsartan | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 14 |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Simvastatin | Simvastatin | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $596.31 · 31 records | Axsome Therapeutics, Inc. | Auvelity, BREZTRI, Cologuard Collection Kit, ELIQUIS, EVENITY, FANAPT, FARXIGA, GEMTESA, Korlym, Leqembi, NURTEC ODT, Qelbree, VRAYLAR, Veozah, Wegovy, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error